# Revatio® (sildenafil) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sildenafil

> The next catalyst for Revatio® (sildenafil), sponsored by Viatris Inc (VTRS), is its topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for Revatio® (sildenafil)?

The next catalyst for Revatio® (sildenafil), sponsored by Viatris Inc (VTRS), is its topline data readout, 2027. Press release filed with the SEC (EX-99): "Topline results are expected in 2027." [Calendar and source filings](https://sec-api.dev/pdufa/sildenafil)

Source: Press release filed with the SEC (EX-99), accession 0001493152-26-037737, https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-08-13. Cite: https://sec-api.dev/pdufa/sildenafil#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Revatio® (sildenafil) |
| Codes |  |
| Sponsor | Viatris Inc (VTRS) https://sec-api.dev/companies/vtrs/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### January 31, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA021845 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20230131, review_priority STANDARD; sponsor_name VIATRIS; product REVATIO (SILDENAFIL CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021845%22

### March 3, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA203109 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20230303, review_priority STANDARD; sponsor_name VIATRIS; product REVATIO (SILDENAFIL CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203109%22
- openFDA Drugs@FDA: "NDA022473 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20230303, review_priority STANDARD; sponsor_name VIATRIS; product REVATIO (SILDENAFIL CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022473%22

### Apr 2023: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-31, last confirmed 2026-03-26.
- SEC Form 10-K (accession 0001401914-26-000004): "In April 2023, we initiated subject enrollment in a Phase 1, single-dose, double-blind, placebo-controlled, 3-way crossover clinical study of Sildenafil Cream using thermography to assess the PD and pharmacokinetic (PK) characterization of Sildenafil Cream." https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231.htm
- SEC Form 10-K (accession 0001401914-25-000012): "In April 2023, we initiated subject enrollment in a Phase 1, single-dose, double-blind, placebo-controlled, 3-way crossover clinical study of Sildenafil Cream using thermography to assess the PD and pharmacokinetic (PK) characterization of Sildenafil Cream." https://www.sec.gov/Archives/edgar/data/1401914/000140191425000012/dare-20241231.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2024-12-16, last confirmed 2024-12-16.
- SEC Form 8-K (accession 0001493152-24-050117): "Phase 3 clinical study of Sildenafil Cream in premenopausal women with FSAD, reflecting the FDA's recommendations, to the FDA in the first quarter of 2025, and that we are targeting mid-2025 for commencement of the Phase 3 study." https://www.sec.gov/Archives/edgar/data/1401914/000149315224050117/form8-k.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-24-050117): "3 clinical study, reflecting the FDA's recommendations, to the FDA in the first quarter of 2025, and is targeting mid-2025 for commencement of the Phase 3 study." https://www.sec.gov/Archives/edgar/data/1401914/000149315224050117/ex99-1.htm

### Jul 2025: interim data readout

- Status: scheduled. Date confidence: month.
- First seen 2025-05-13, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0001641172-25-009939): "Review of interim data by the study's data safety monitoring board, an independent group of experts which evaluates the safety and integrity of the study, scheduled for July 2025." https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/ex99-1.htm

### 2027: topline data readout

- Status: scheduled. Date confidence: year.
- First seen 2026-08-13, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001493152-26-037737): "Topline results are expected in 2027." https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sildenafil.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Revatio® (sildenafil) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sildenafil

```bibtex
@misc{secapidev_pdufa_sildenafil_20261116,
  title        = {Revatio® (sildenafil) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sildenafil}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sildenafil_20261116","title":"Revatio® (sildenafil) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sildenafil","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
